news

MAK-SYSTEM announces strategic partnership with Northern Ireland Blood Transfusion Service of “vein to vein” management from donor to recipient. MAK-SYSTEM is proud to be the partner of Northern Ireland Blood Transfusion Service to deliver safe, compliant and efficient blood management to patients, donors and clinicians. The partnership was announced by NI Health Minister Robin Swann … Read more

MAK-SYSTEM’s innovative MAK.care service successfully went live at New Zealand Blood Service on February 11th 2024. MAK.care is the first Global Platform for blood and biologics, delivered as a service.  New Zealand Blood Service now has full end to end automation of the nationwide vein-to vein operations from blood donation to transfusion, securely managed in the cloud by MAK-SYSTEM on … Read more

We are thrilled to share our BECS, eProgesa, is now 510k cleared from the FDA, including for cloud hosting with our MAK.Care service.! On 3rd November FDA informed us that our blood establishment computer system ePROGESA v5.0.3, is cleared under the 510(k) regulatory pathway and can be promoted and sold in the U.S. This 510(k) … Read more

We’re thrilled to announce that COSMAS, our new digital platform for Tissue, Stem Cell & Gene Therapies is CE-marked and registered for the EU market! COSMAS is now a CE-marked In Vitro Diagnostic medical device and can be sold in the European Union as of November 1st. Our COSMAS team and Quality & regulatory team … Read more

Damjan Manchevski, Director of Strategic Accounts & General Manager for Balkans at MAK-System will take to the stage at the 6th Congress of Macedonian Society for Transfusion Medicine talking about the New Age of Digital Transformation in Blood Transfusion.

MAK-SYSTEM is excited to showcase our latest Blood & Biologics management technologies at the AABB 2023 Annual Meeting in Nashville, 14-17 October

We are pleased to announce a 10 year strategic partnership with New York Blood Center.

MAK-SYSTEM announce strategic partnership with Amazon Web Services (AWS) allowing for more efficient and scalable connectivity for all stakeholders, including blood centres, donors, healthcare providers and the pharmaceutical and biotech industries.